Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...
We never sold the combination in the countries where it's banned. Our exports were done only after getting valid product permissions from the State FDA and required export NOCs,' said Arvind Sharma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback